Join
Live feed
·
PRReleasevia Quantisnow
TuHURA Biosciences Inc. logo

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

ByQuantisnow·Wall Street's wire, on your screen.
HURA· TuHURA Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HURA (TuHURA Biosciences Inc.) and more on Quantisnow.